Commodore Capital’s Adicet Bio ACET Stock Holding History

Commodore Capital’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-85,895	Closed	-$3.23M	–	36
2024 Q1	$3.23M	Buy	+85,895	New	+$3.55M	0.22%	37

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Commodore Capital's ACET Position: Q2 2024 in Review

Commodore Capital sold out of Adicet Bio (ACET) in Q2 2024, closing a stake of 85,895 shares — an estimated $3.23M sold.

Commodore Capital first reported a position in ACET in Q1 2024 and held it in 1 quarter. The position peaked at $3.23M in Q1 2024. 86 funds tracked by Wall St. Rank hold ACET as of Q2 2024.

Commodore Capital reported no remaining Adicet Bio position as of Q2 2024 after selling out during the quarter.
Commodore Capital sold 85,895 Adicet Bio shares in Q2 2024, an estimated $3.23M.
Commodore Capital first reported a position in Adicet Bio in Q1 2024 and held it in 1 quarter.
Commodore Capital's Adicet Bio position peaked at $3.23M in Q1 2024.
86 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2024.

Based on Commodore Capital's 13F filing for Q2 2024, filed 14 Aug 2024.